Aquatic Capital Management LLC Takes Position in Evolent Health, Inc. (NYSE:EVH)

Aquatic Capital Management LLC bought a new position in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 75,110 shares of the technology company's stock, valued at approximately $845,000. Aquatic Capital Management LLC owned 0.06% of Evolent Health as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health during the 4th quarter valued at about $26,000. R Squared Ltd purchased a new position in Evolent Health during the fourth quarter valued at approximately $31,000. AlphaQuest LLC increased its holdings in Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after acquiring an additional 3,031 shares during the period. Parkside Financial Bank & Trust increased its holdings in Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after acquiring an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC bought a new stake in Evolent Health during the 4th quarter worth approximately $61,000.

Insider Activity at Evolent Health

In other Evolent Health news, Director Brendan B. Springstubb bought 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the completion of the acquisition, the director now directly owns 11,842 shares in the company, valued at $103,617.50. The trade was a 73.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Daniel Joseph Mccarthy acquired 11,040 shares of Evolent Health stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the transaction, the president now owns 389,004 shares in the company, valued at approximately $3,504,926.04. This trade represents a 2.92 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 74,000 shares of company stock worth $666,315 in the last 90 days. Company insiders own 1.60% of the company's stock.

Analyst Upgrades and Downgrades

EVH has been the subject of a number of recent analyst reports. Royal Bank of Canada reduced their price target on shares of Evolent Health from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Tuesday, January 14th. JPMorgan Chase & Co. lowered their price target on Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a report on Monday, March 10th. UBS Group dropped their price target on Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, January 16th. Citigroup lowered their target price on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Finally, Truist Financial cut their price target on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $17.71.

Evolent Health Trading Down 1.4 %

EVH stock traded down $0.15 during midday trading on Tuesday, hitting $10.41. The company had a trading volume of 224,735 shares, compared to its average volume of 2,362,825. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -12.69 and a beta of 1.20. Evolent Health, Inc. has a 52 week low of $8.35 and a 52 week high of $33.63. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock's 50 day moving average price is $9.50 and its 200 day moving average price is $11.83.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $646.54 million for the quarter, compared to analysts' expectations of $650.92 million. As a group, equities research analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.